SANUWAVE Health, Inc. Provides Revenue Guidance for the Second Quarter of 2023
May 12, 2023 at 02:12 pm
Share
SANUWAVE Health, Inc. provided revenue guidance for the second quarter of 2023. The company has continued to have constrained inventory supply during first quarter of 2023. Despite this, the anticipate revenue growth of approximately 15% to 25% during second quarter of 2023, compared to second quarter of 2022.
The company believes that supply is further improving and that the company will observe continued increase in revenue growth in second quarter of 2023.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
